

1804

Lo 0300  
01-10-95

PATENT

Q Williams  
10/28/95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Gefter et al.  
Serial No. : 08/300,510  
Filed : September 2, 1994  
Attorney Docket No. : 092.0 US  
For : COMPOSITIONS AND METHODS FOR  
ADMINISTERING TO HUMANS, PEPTIDES  
CAPABLE OF DOWN REGULATING AN  
ANTIGEN SPECIFIC IMMUNE RESPONSE

10/13/1994



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231 on January 12, 1995.

By *Lorraine Miller Doyle*  
Lorraine Miller Doyle

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Honorable Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

Transmitted herewith is:

- an Information Disclosure Statement
- a 6-page PTO 1449 citing 34 references
- the references cited on PTO Form 1449 are enclosed

1.  This Information Disclosure Statement is filed before the later of:

- a. three months from the filing date of this national application;
- b. three months from the date of entry of the national stage as forth in 37 CFR 1.491 in an international application, or;
- c. the mailing date of a first Office Action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

2. [ ] This Information Disclosure Statement is filed after the events noted in paragraph 1, but before either:

- a. a final action under 37 CFR 1.113, or
- b. a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(c) also enclosed is:

[ ] a fee under 37 CFR 1.17(p) in the amount of \$200.00; or  
[ ] a certification as stated below.

3. [ ] This Information Disclosure Statement is filed before the payment of the issue fee, but after either:

- a. a final action under 37 CFR 1.113, or
- b. a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(d) also enclosed is:

- a. a certification, as stated below;
- b. a Petition requesting consideration of the Information Disclosure Statement, and
- c. the Petition fee set forth in 37 CFR 1.17(i)(1) in the amount of \$130.00.

Certification

The undersigned also states:

[ ] Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or

[ ] No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

The fees indicated above are:

**TOTAL FEES: \$0**


Please charge Deposit Account No. 09-0087 in the amount of \$\_\_\_\_\_

No fee is required.

The Commissioner is hereby authorized to charge any underpayment of any fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 09-0087.

This form is being submitted in triplicate for accounting purposes.

Respectfully submitted,



Darlene A. Vanstone, Reg. No. 35,729  
Attorney for Applicants

Date: January 12, 1995

ImmuLogic Pharmaceutical Corporation  
Patent Department  
610 Lincoln Street  
Waltham, MA 02154  
Telephone: 617-466-6000

B:6580